We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Serum Protein Assays Validated for Autoanalyzer

By LabMedica International staff writers
Posted on 24 Feb 2011
Fourteen human serum protein assays have been developed and validated for fully automated, user-programmable analyzer. More...


The autoanalyzer is designed to perform potentiometric and photometric assays in serum, plasma, urine, and cerebrospinal fluid, as well as various supernatant sample types.

The assays were developed by scientists at the Foundation for Blood Research, (Scarborough, ME, USA), using de-identified, surplus serum samples stored at -20 °C for less than two months. Samples were selected to encompass a broad range of analyte concentrations and were used for the method comparison studies. The 14 human serum proteins assayed were 1-antitrypsin, 2-macroglobulin, albumin, apolipoproteins AI and B, complement components 3 and 4, haptoglobin, immunoglobulins A, G, and M, orosomucoid, transferrin, and transthyretin. The autoanalyzer used was the versatile Roche cobas c 501, (Roche Diagnostics; Indianapolis, IN, USA), which is from their 6000 series.

Immunoturbidimetric assays for 12 of the 14 proteins were developed using monospecific goat antihuman serum from Midland BioProducts Corporation (Boone, IA, USA). For assaying α-1-antitrypsin and α-2-macroglobulin, goat antihuman serum was obtained from International Immunology Corporation (Murrieta, CA, USA) and DiaSorin (Stillwater, MN, USA), respectively.

The scientists obtained excellent precision at low, normal, and high physiologic concentrations of each protein. Linearity for each method was within 5% of the expected value throughout the calibration range, and method comparison studies to commercial assays were in good agreement. No significant interference was observed from bilirubin, up to 414 mg/L, hemoglobin up to 8.9 g/L, triglyceride, up to 28 g/L, or rheumatoid factor, up to 3,930 IU/mL. Calibration was stable for at least 14 days. The instrument's small reaction cell allowed conservation of nearly 60% of the specimen and reagent volume compared with another system.

The scientists concluded that these newly developed assays provide precise and accurate results with high throughput, but without the associated cost of a dedicated instrument. The study was published on January 19, 2011, in the Journal of Clinical Laboratory Analysis.

Related Links:

Foundation for Blood Research
Roche Diagnostics
Midland BioProducts Corporation
International Immunology Corporation
DiaSorin



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Turbidimetric Control
D-Dimer Turbidimetric Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.